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Abstract
Introduction: In triple negative breast cancers (TNBC) the initial response to chemotherapy is often favorable, but
relapse and chemotherapy resistance frequently occur in advanced disease. Hence there is an urgent need for targeted
treatments in this breast cancer subtype. In the current study we deep sequenced DNA of tumors prior to chemotherapy
to search for predictors of response or resistance.
Methods: Next generation sequencing (NGS) was performed for 1,977 genes involved in tumorigenesis. DNA from 56
pre-treatment TNBC-biopsies was sequenced, as well as matched normal DNA. Following their tumor biopsy, patients
started neoadjuvant chemotherapy with doxorubicin and cyclophosphamide. We studied associations between genetic
alterations and three clinical variables: chemotherapy response, relapse-free survival and BRCA proficiency.
Results: The mutations observed were diverse and few recurrent mutations were detected. Most mutations were
in TP53, TTN, and PIK3CA (55 %, 14 %, and 9 %, respectively). The mutation rates were similar between responders
and non-responders (average mutation rate 9 vs 8 mutations). No recurrent mutations were associated with
chemotherapy response or relapse. Interestingly, PIK3CA mutations were exclusively observed in patients proficient for
BRCA1. Samples with a relapse had a higher copy number alteration rate, and amplifications of TTK and TP53BP2 were
associated with a poor chemotherapy response.
Conclusions: In this homogenous cohort of TNBCs few recurrent mutations were found. However, PIK3CA mutations
were associated with BRCA proficiency, which can have clinical consequences in the near future.
Introduction
Neoadjuvant chemotherapy (NAC) is the standard of
care for locally advanced breast cancer. For triple nega-
tive breast cancer, which is characterized by the absence
of expression of estrogen receptor (ER), progesterone re-
ceptor (PR) and human epidermal growth factor recep-
tor 2 (HER2), it is currently the only available systemic
treatment option. Approximately half of all TNBC reaches
a pathological complete remission (pCR) upon NAC.
However, tumors without a pCR often relapse. When dis-
tant metastases develop, prognosis is poor, with a median
post recurrence survival of only one year [1, 2]. As it is im-
possible to predict which patients will respond and which
ones will not, predictive biomarkers are urgently needed.
The same is true for targeted treatments, particularly for
non-responding tumors.
With the introduction of next generation sequencing
(NGS), tumor collections have been sequenced to
categorize mutations and to find new treatment tar-
gets [3–5]. Many new mutations and several important
signaling pathways have been identified. However, one
of the main findings of the sequencing efforts is the
marked heterogeneity within breast cancer. This hetero-
geneity is highlighted by the fact that recurrent mutations
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are infrequent. No two tumors have the same molecular
make up. Consequently, subsequent studies attempting to
identify broad mechanisms of chemotherapy resistance
are not likely to be successful. There are many different
routes to tumorigenesis, and each tumor has its own
sequence of tumor-causing molecular events. The emer-
gence of drug resistance may be driven by additional mu-
tations and add a further level of complexity. Clinical data
are not available for most studies, precluding the integra-
tion of molecular and clinical data. In addition, most exist-
ing molecular studies have been undertaken on a broad
mix of breast cancer samples, with widely varying clinical
stage or molecular subtype. A more homogeneous study
population with well-characterized clinical data may be re-
quired to find clinical predictive factors.
To find mutations predicting chemotherapy benefit in
TNBC, we performed NGS in a clinically well-characterized
cohort. We sequenced an NGS panel covering 1,977 genes
involved in tumorigenesis and treatment. We sequenced
pretreatment biopsies from patients with a good response
and patients with a poor response, to identify chemotherapy
predictive markers. The purpose of this study was twofold:
1) to find chemotherapy response-predictive biomarkers
and 2) to identify new treatment targets.
Methods
Patients and tumor biopsies
Pre-treatment biopsies and peripheral blood samples
were obtained from 56 patients with untreated, primary
triple negative breast cancer. All patients had received
neoadjuvant treatment at the Netherlands Cancer Insti-
tute between 2004 and 2013 as part of ongoing clinical
trials, or were treated off protocol according to the
standard arms of one of these studies [6] (NCT00448266,
NCT01057069). The ethical committee of the Netherlands
Cancer Institute approved the studies and all patients gave
informed consent (reference numbers of Ethical approval:
PTC06.1725/N06IAA and PTC09.2716/M09TNM). All
tumors were either at least 3 cm in size, or the presence of
axillary lymph node metastases had been established by
fine needle aspiration or pre-treatment sentinel node bi-
opsy. Biopsies were taken using a 14-G core needle under
ultrasound guidance. After collection, specimens were
snap-frozen in liquid nitrogen and stored at −80 °C. Each
patient had two or three biopsies taken to ensure that
enough tumor material was available for both diagnostic
and research purposes.
All patients started NAC with three courses of 2-weekly
administrations of cyclophosphamide and doxorubicin
(ddAC). The selection of the chemotherapy regimen for
the fourth to the sixth courses depended on the specific
clinical trial and could consist of continuation of ddAC
in the case of a favorable magnetic resonance imaging
(MRI) response (for criteria see previous publication
[7]), randomization to intensive carboplatin-based chemo-
therapy or a switch to a combination of capecitabine and
docetaxel in the case of an unfavorable MRI response. All
patients subsequently underwent surgery, either breast
conserving or mastectomy. The clinical results of these
strategies have not been published because the studies are
ongoing (NCT00448266, NCT01057069).
Pathology
Triple negative status was defined by the absence of ER
and PR expression and no amplification of HER2. ER
(Roche Diagnostics cat. no. 5278406001 (Roche, Basel,
Switserland))- and PR (Roche Diagnostics cat. no.
5278392001)-negativity was defined as immunohisto-
chemical (IHC) staining of fewer than 10 % of tumor cell
nuclei. None of the samples in this cohort had between
1 % and 10 % positive tumor cell nuclei, so all samples
fulfilled the ASCO/CAP criteria for triple negativity.
Negativity for HER2 (Roche Diagnostics cat. no.
5278368001) amplification was present if IHC staining
was graded as 0 or 1+. In the case of 2+ or 3+ staining,
chromogenic in situ hybridization was performed to de-
termine HER2 amplification (gene copy number ≥6 per
tumor cell). Chemotherapy response was assessed by
microscopic examination of the surgery resection speci-
men. The complete absence of any invasive tumor cells
in both the breast and the lymph nodes was considered
as a pCR. All other responses were assigned to the no-
pCR group. An experienced breast cancer pathologist
(JW) reviewed all pathology slides.
BRCA analysis
The series was well-characterized for BRCA function.
Briefly, germ line DNA was isolated from peripheral
blood lymphocytes of affected patients. We used mutation-
scanning methods. The protein truncation test was used
for exon 11 of BRCA1 and exons 10 and 11 of BRCA2.
The remaining exons were tested using denaturing gradi-
ent gel electrophoresis. Confirmation of aberrant samples
was done by Sanger sequencing [8]. In addition, multiplex
ligation-dependent probe amplification (MLPA) was per-
formed using MLPA kit P087 (BRCA1) to detect large gen-
omic deletions or duplications in the genes.
Hypermethylation of the BRCA1 promoter was deter-
mined using methylation-specific MLPA analysis, according
to the manufacturer’s protocol (MLPA assay ME005-
custom, MRC-Holland, Amsterdam, The Netherlands).
For normalization and analysis the Coffalyzer program
was used (MRC-Holland). According to the manufac-
turer’s protocol, we used a cutoff of 20 % to call a sam-
ple methylated [9]. Employing this cutoff, methylated
samples have very low BRCA1 gene expression [10, 11],
which was also true for this series (Additional file 1:
Figure S1).
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Library preparation
DNA was isolated from frozen biopsies with a minimal
tumor percentage of 50 %. Tumor cell percentage was
assessed by an experienced breast pathologist (JW). Isolation
was performed with (Qiagen, Venlo, the Netherlands) DNA
mini kit. Matched normal DNA was obtained from periph-
eral blood and extracted by DNAzol and purified with Qia-
gen DNeasy kit. Samples were interrogated by a designed
“Cancer mini-genome” consisting of 1,977 cancer genes
[12]. This set comprises genes involved in DNA repair, cell
cycle, apoptosis, epigenetic modification (methylation,
acetylation), angiogenesis (vascular endothelial growth factor
(VEGF) pathway), and genes from the epidermal growth fac-
tor receptor (EGFR), mammalian target of rapamycin
(mTOR), insulin, TP53, transforming growth factor (TGF)-
beta, Notch, Wnt and hedgehog pathways, known tumor
suppressor and proto-oncogenes, and all additional kinases
not present in any of the above mentioned processes. Genes
are listed in Additional file 2: Table S1. Barcoded fragment
libraries were generated from 300–600 ng of isolated DNA
from tumor and reference samples as previously described
[13]. Pools of libraries were enriched for 1,977 cancer-
related genes using (SureSelect technology, Agilent, Santa
Clara, California, US). Enriched libraries were sequenced to
achieve an average coverage of at least 150× on a (SOLiD
5500xl, Applied Biosystems, Waltham, Massachusetts, US)
instrument according to the manufacturers’ protocol. Se-
quencing statistics are available in Additional file 3: Table S2.
Sequence data analysis
Sequence reads were mapped on the human reference gen-
ome version 19 (GRCh37), using BWA (−c –l 25 –k 2 –n
10) [14] and variant calling was done using a custom pipe-
line identifying variants with at least 10× coverage, a 20 % al-
lele frequency, and multiple (> = 2) occurrences in the seed
(the first 25-bp most accurately mapped part of the read)
and support from independent reads (> = 3). Validation of
our custom variant-calling pipeline is described in Nijman et
al. [15]. Putative somatic variants were identified by subse-
quently genotyping all variant positions in the raw datasets
of both the tumor and reference sample using samtools
mpileup, to ensure the absence of variant alleles in the refer-
ence sample; only positions showing less than 5 % variant al-
leles in the reference sample were considered somatic. Next,
somatic variants with a minor allele frequency >0.01 in non-
Catalogue of Somatic Mutations in Cancer (COSMIC) pop-
ulations in dbSNP were filtered out, as were variants seen >
= 1× homozygously or > = 3× heterozygously in reference
samples in our in-house database and variants with an allele
frequency <25 % if the coverage was <50×. Finally, manual
curation was performed to remove obvious noise in poorly
mapped regions. For the analysis of association with clinical
data and the pathway analysis, we included only putative
driver mutations defined as either 1) mutations with a major
effect on protein expression, defined as a) truncating mu-
tations, indels, splice acceptors/donors, initiator codon
variants or b) non-synonymous mutations predicted to be
damaging according to PolyPhen [16] and/or SIFT [17], or
2) known COSMIC mutations.
Copy number analysis was done by comparing depth of
coverage in reference and tumor samples using the robust z
score according to the method of Iglewicz and Hoaglin [18].
Briefly, the median and median absolute deviation of cover-
age per exon of all reference samples, normalized on the
total number of reads per sample, was calculated to deter-
mine the coverage distribution. The z -scores (i.e., the differ-
ence between the coverage of the tumor sample and the
median coverage of the reference pool of normal samples,
multiplied by a correction factor of 0.6745, and divided by
the median absolute deviation of the reference pool) were
calculated for all exons of each tumor sample. The z score
of the total gene was calculated by taking the average of the
z scores per exon. As we noticed an effect of GC-content on
the exon-coverage profiles in some, but not all samples, we
used unsupervised hierarchical clustering of the normalized
coverage per exon of all samples. Two clear clusters were
formed, but 12 samples (including both tumor and reference
samples) could not be placed in either cluster. Exon cover-
age of the tumor samples was then compared to the refer-
ence samples within the same cluster. Genes with z scores >
= 10 were considered high-level amplifications; a z score > =
3 indicates copy number gain and < = −3 copy number loss.
Sanger sequencing for validation of PIK3CA mutations
Samples were analyzed by Sanger Sequencing using a Big-
Dye Terminator Cycle Sequencing Kit and ABI 3730 capil-
lary sequencer (Life Technologies/Applied Biosystems,
Waltham, Massachusetts, US).
Statistics: association of sequencing data with clinical
information
Statistical analyses were performed with R/Bioconductor
[19]. We focused on three clinical variables: 1) pCR, 2) re-
lapse and 3) BRCA proficiency. We encoded each of the
clinical variables into a binary variable and then studied as-
sociations at the gene and at the pathway levels: association
between mutations in an individual gene and the given
clinical variable was tested using Fisher’s exact test of the
presence/absence of a mutation in a sample and the pres-
ence/absence of the clinical variable. The pathway analysis
was based on a list of 29 pathways from the Kyoto
Encyclopedia of Genes and Genomes (KEGG), including at
least three genes targeted in the sequencing experiments.
We considered a pathway to be mutated if at least one of
its genes was found mutated. We then performed the Fish-
er’s exact test of the presence/absence of a mutation in a
given pathway and the presence/absence of the clinical
variable in the various samples. All tests were corrected for
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multiple testing using the Benjamini-Hochberg method. In
all analyses, associations were considered significant when
the adjusted p value was <0.05.
Results
Description of the dataset
We performed deep sequencing on a set of fifty-six triple
negative pre-treatment biopsies, scheduled to receive NAC.
The pathological complete remission rate was 45 %
(Table 1). With a median follow up of 2.5 years, nine
patients had a relapse (16 %). Twelve patients had a BRCA1
or BRCA2 germline mutation, and seventeen biopsies
showed BRCA1 promoter methylation. In total, BRCA
function (based on either a BRCA1/2 mutation or BRCA1
promoter methylation) was impaired in at least 29 tumors
(52 %). This number could be higher as BRCA1 germline
screening was not performed for five cases, as these cases
did not qualify for routine diagnostic BRCA1 and BRCA2
germline testing (based on age, family history). Between 1
and 36 somatic mutations per sample were detected (10
mutations on average; Additional file 4: Table S3).
Few recurrent mutations in TNBC
The somatic mutation rates were similar for responders
and non-responders (average mutation rate of nine versus
eight mutations per tumor, p = 0.32). The mutation
spectrum was broad with few recurrent mutations in
the dataset. Figure 1 shows the mutations occurring in
three or more samples. Mutations in TP53, TTN and
PIK3CA were the most frequently observed alterations
in this study (55 %, 14 %, and 9 %, respectively). Poten-
tially dubious genes were extracted from Lawrence et
al. [20] and indicated as such in the mutation data
(Additional file 4: Table S3).
Association of mutations with clinical variables
There were no putative driver mutations significantly as-
sociated with either chemotherapy response (pCR rate)
or with relapse (Additional file 5: Table S4). An explan-
ation could be the heterogeneous nature of TNBCs and
lack of recurrent mutations in TNBCs.
Next, we assessed whether any putative driver mutations
were associated with BRCA deficiency, either resulting
from a germline mutation or from promoter methylation.
PIK3CA mutations were exclusively observed in patients
with functional BRCA genes (5/27 (19 %)) versus 0/
29 in the patients with a BRCA mutation or BRCA1
promoter methylation (p = 0.02, adjusted p value (p-adj) =
0.11) (Table 2). Tumors with BRCA impairment may de-
velop via different routes than tumors with functioning
BRCA genes, and the PI3K pathway may play a role in the
latter. This finding has also been recently observed in an
independent dataset [21]. All PIK3CA mutations were
confirmed with Sanger sequencing.
Pathway analysis
We next investigated whether mutations in different genes
would cluster in some known pathways. Using KEGG, we
derived a pathway mutation status based on its gene mem-
bers (see “Methods”) and looked for association with the
clinical variables (Table 3; Additional file 6: Table S5 and
Additional file 7: Table S6). Calcium signaling was in-
versely associated with a pCR (p = 0.03), as was Notch sig-
naling (p = 0.03). BRCA mutated or methylated tumors
Table 1 Patient and tumor characteristics
Characteristic Values
(n = 56 patients)
Age
Median, range 40 (23–74)
Tumor stage
1 5 (9)
2 40 (71)
3 7 (13)
4 4 (7)
Nodal stage
Lymph nodes negative 19 (34)
Lymph nodes positive 37 (66)
Grade
II 18 (32)
III 34 (61)
Not determined 4 (7)
Chemotherapy
6 × dose dense doxorubicin/cyclophosphamide 43 (77)
3 × dose dense doxorubicin/cyclophosphamide,
3 × docetaxel/capecitabine
5 (9)
4 × dose dense doxorubicin/cyclophosphamide,
2 × cyclophosphamide/thiotepa/carboplatin
8 (14)
BRCA germline mutation status (Sanger sequencing)
BRCA1 mutation 10 (18)
BRCA2 mutation 2 (4)
Wildtype 39 (70)
Not determined 5 (9)
BRCA1 promoter methylation
No BRCA1 methylation 39 (70)
BRCA1 methylation 17 (30)
Response breast and lymph nodes
No pathological complete remission 31 (55)
Pathological complete remission 25 (45)
Relapse
No relapse 47 (84)
Relapse 9 (16)
Values are n (%) unless stated otherwise
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were associated with mutations in the Wnt signaling
pathway (p = 0.06). However, after correcting for multiple
testing, none of the associations remained statistically sig-
nificant. No pathways were associated with relapse.
Copy number analysis
Fifty out of fifty-six tumors had NGS data suitable for
copy number analysis. We identified high-level, focal
amplifications of several growth factor receptors such as
EGFR and FGFR2, and amplification of AIM1 in three
samples, MET amplification in three samples and CCNE1
and PIK3CA in single cases (Additional file 8: Figure S2).
Multiple focal, high-level amplifications were visible
in several samples, affecting up to five different chro-
mosomes per patient, while other samples showed no
such events. We also detected recurrent gains of cyclins
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Fig. 1 Heatmap of mutations occurring in two or more samples. Blue box mutation; left the three clinical variables; yellow subsequently a BRCA1 mutation
or methylation, a pathological complete remission (pCR), and a recurrence. Gray samples with follow up time that was not long enough to be included in
the relapse analysis
Table 2 Association of mutations with BRCA proficiency
Gene BRCA mutated/
methylated (number)
BRCA proficient
(number)
BRCA mutated/methylated,
and mutated (number)a
BRCA proficient and
mutated (number)a
P value Adjusted p value
PIK3CA 29 27 0 5 0.02 0.11
TP53 29 27 18 12 0.28 0.59
TTNb 29 27 4 1 0.35 0.59
ALMS1 29 27 1 2 0.60 0.76
HSP90AB1 29 27 2 1 1.00 1.00
aAll samples with a BRCA mutation/methylation and a mutation in the respective gene, and applies likewise to the BRCA proficient and mutated column, Table 3,
and Table 4. bThe TTN gene is often mutated due to its greater length and may not be cancer-related (see also Additional file 4: Table S3)
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(CCND1, CCND2), MYC and FGFR1. Chromosome
1q and 8q (including MYC) showed gains in several
samples, both events were frequently detected in the
same sample.
Patients with a relapse or without a pCR in the breast
had a higher number of genes with copy number alterations
(CNA) than patients without a relapse or with a pCR in the
breast (p = 0.0091 and p = 0.023, respectively). Specific am-
plifications and deletions were associated with response, re-
lapse and BRCA proficiency. Most interesting is that TTK
and TP53BP2 amplifications were associated with a poor
response (p = 0.02 and p = 0.06, respectively). However,
after correction for multiple testing, the p values were no
longer significant. Table 4 gives an overview of the CNAs
related to the clinical phenotypes. TTK is involved in mi-
totic checkpoint, and over-expression was recently reported
to be associated with TNBC. TTK might be an attractive
therapeutic target [22]. TTK and TP53BP2 amplifications
were also observed in Nimblegen copy number data of the
same samples (Additional file 9: Figure S3).
Discussion
In this study we deep-sequenced a cohort of 56 pre-
treatment breast cancer biopsies to find chemotherapy
predictive biomarkers and new treatment targets. We
found that TNBC was very heterogeneous with few re-
current mutations. As a result, we were not able to find
biomarkers associated with chemotherapy response and
relapse. We found that tumors without BRCA impairment
(through a mutation or through BRCA1-promoter methy-
lation) frequently had PIK3CA mutations.
The heterogeneous nature of TNBC has already been
described by others [3, 5, 23] and makes it difficult to
find predictive biomarkers. There may well be hundreds
of different mutations associated with resistance to stand-
ard chemotherapy. This fact would explain why overall
comparison of groups of sensitive versus resistant tumors
does not lead to candidate markers. The same problem
exists for gene expression studies: due to several factors,
among which the highly variable makeup of tumors may
be central, it has proven to be extremely difficult to find
predictive profiles [24]. Different genes may explain resist-
ance in subgroups of tumors as we have shown for HER2-
negative tumors in our gene expression studies [25, 26]. A
possibility to analyze NGS mutation data in a different
manner is to investigate logical combinations of the muta-
tion status of several genes and how such a combination
relates to a clinical outcome variable of interest. For in-
stance, mutation in gene A and not in gene B could be
predictive of response. However, the number of possible
combinations is so large that such an analysis is not prac-
tical with datasets of the size presented here. In this study
we have used external knowledge (KEGG pathways) to
focus on the combination of some specific subsets of
genes. It would be interesting to investigate combinations
of genes beyond these annotated pathways.
Previous research by our group and by others has shown
that a proportion of TNBC shares similarities with BRCA1-
mutated breast cancers [10, 27–29]. This phenotype is often
called “BRCAness”. As BRCA1 and BRCA2 are involved in
the repair of DNA double-strand breaks (DSBs), a process
called homologous recombination, dysfunctional BRCA
Table 3 Association of KEGG pathways with clinical variables
A. Pathological complete remission (pCR)
Pathway Genes in
pathway
Genes
mutated
pCR (number) No pCR
(number)
pCR and
mutated (number)
No pCR and
mutated (number)
P value Adjusted
p value
Calcium signaling pathway 177 6 25 31 0 6 0.03 0.41
Notch signaling pathway 47 4 25 31 4 0 0.03 0.41
TGF-beta signaling pathway 85 6 25 31 0 5 0.06 0.41
Phosphatidylinositol signaling system 78 11 25 31 4 12 0.08 0.41
Focal adhesion 200 25 25 31 7 16 0.10 0.41
B. BRCA proficiency
Pathway Genes in
pathway
Genes
mutated
BRCA mutated/
methylated
(number)
BRCA
proficient
(number)
BRCA mutated/
methylated, and
mutated (number)
BRCA proficient
and mutated
(number)
P value Adjusted
p value
Wnt signaling pathway 151 12 29 27 21 12 0.06 0.78
Jak-STAT signaling pathway 155 3 29 27 2 6 0.14 0.78
Regulation of actin cytoskeleton 214 16 29 27 6 11 0.15 0.78
MAPK signaling pathway 268 28 29 27 21 14 0.17 0.78
mTOR signaling pathway 52 5 29 27 3 7 0.17 0.78
TGF transforming growth factor, MAPK mitogen activated protein kinase, mTOR mammalian target of rapamycin
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could render a tumor hypersensitive to drugs that (ul-
timately) induce DNA DSBs during the DNA replication
phase, such as the PARP inhibitors or alkylating chemo-
therapy. In this study we observed that 22 % of the tu-
mors had a BRCA mutation and 30 % had BRCA1
promoter methylation, indicating that BRCA inactiva-
tion is observed in over half of the tumors. PIK3CA mu-
tations were only observed in the tumors proficient for
BRCA. Our group has been extensively studying tumors
with BRCA1 promoter methylation or a BRCA1-like
genomic profile. We found that these BRCA1-like tu-
mors resemble BRCA1 mutation carriers in multiple re-
spects, i.e., age, grade and good chemotherapy response
[29]. Most importantly those BRCA1-like tumors have an
excellent response to DSB-inducing chemotherapy [30].
The association between non-BRCA1-like tumors and
PIK3CA mutations was also seen in an independent
study [21]. Other studies found that PIK3CA mutations
are more frequent in HER2+ and luminal breast cancer; it
might be that we defined a subgroup of TNBCs where
PIK3CA mutations are also frequent, i.e., the non-BRCA
subgroups. Another consequence of this finding could be
that some non-BRCA-related tumors could be susceptible
to PIK3CA inhibitors.
As far as we know this is the first deep sequencing study
comparing well-responding and poorly-responding breast
tumors in the neoadjuvant setting to identify biomarkers.
Balko et al. [31] performed NGS on TNBC after neoadju-
vant treatment. This study focused on a cohort of cancers
with macroscopic residual disease after NAC, which is as-
sociated with poor survival. When we compare our results
with the Balko study we see the following. The Balko
study detected a higher frequency of several targetable al-
terations when comparing data with The Cancer Gen-
ome Atlas (TCGA) Breast [3]. These alterations
included MCL1, PTEN, and JAK2. As expected, the per-
centage of these mutations in our study was more com-
parable to the Balko data than to TCGA (Additional file
10: Table S7). Whereas the Balko dataset contained only
samples that had been taken after neoadjuvant chemother-
apy, the TCGA cohort contains all clinical breast cancer
stages. However, the Balko series only consists of tumors
with a poor response to chemotherapy response, whereas
our series consists of both responding and non-responding
tumors. We also detected a high percentage of specific
copy number alterations, like DDR2, PYGO2 and SCYL3.
As the Balko study sequenced only 182 oncogenes, those
genes were not in their sequencing panel.
Table 4 Association of copy number variations with clinical variables
A. Pathological complete remission (pCR)
Gene pCR (number) No pCR (number) pCR and CNV (number) No pCR and CNV (number) P value Adjusted p value
TTK 23 28 0 8 0.02 0.95
TP53BP2 23 28 4 15 0.06 0.95
SNAI2 23 28 1 8 0.09 1.00
STK3 23 28 1 8 0.09 1.00
ABL2 23 28 7 3 0.11 1.00
B. Relapse
Gene Relapse
(number)
No relapse
(number)
Relapse and
CNV (number)
No relapse and
CNV (number)
P value Adjusted p value
SNAI2 8 32 4 1 0.03 0.14
MAPK15 8 32 5 3 0.06 0.14
TTN 8 32 0 9 0.07 0.65
PARP10 8 32 6 4 0.08 0.14
STYK1 8 32 0 7 0.11 0.77
C. BRCA proficiency
Gene BRCA mut/meth
(number)
BRCA proficient
(number)
BRCA mut/meth and
CNV (number)
BRCA proficient
and CNV (number)
P value Adjusted p value
IFT81 27 24 1 8 0.001 0.36
SNAI2 27 24 1 8 0.01 0.36
TNFAIP3 27 24 9 0 0.01 0.88
PLCXD3 27 24 5 11 0.02 1.00
CCNB2 27 24 10 1 0.06 1.00
mut/meth mutated/methylated, CNV copy number variation
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A limitation of this study is the small number of samples
with relapse. This fact limits the power and reduces the
likelihood of finding associations with relapse. However, if
there were strong associations with relapse they would
have been picked up.
Although our dataset is small with 56 tumors, and pre-
cludes us from making any firm conclusions about markers
associated with neoadjuvant chemotherapy response in
TNBC, we can draw several potentially important con-
clusions. First, the mutation spectrum remains diverse
even in a carefully selected and untreated group of pa-
tients with TNBC from the same clinical stage (locally
advanced breast cancer, i.e., larger than 3 cm and/or posi-
tive lymph nodes). In addition, all samples were from the
same institute and the laboratory procedures were thor-
oughly monitored: tumor percentage was 50 % or more, a
matching normal DNA sample was available for every
tumor, and pathology assessment of the whole series had
been performed by a single specialized breast pathologist
(JW). Our results strongly suggest that every tumor has its
unique molecular makeup. Second, we found that PIK3CA
mutations were specifically associated with BRCA1 profi-
cient tumors, a finding that was also observed in another
study [21]. This finding may have clinical consequences.
This study shows that it is increasingly important to have
large series of homogenous sample series, with clinically
well-annotated data.
Conclusions
Two important conclusions can be drawn from these data.
First, TNBC is heterogeneous. Even in a homogenous, clin-
ically well-annotated sample series, few recurrent muta-
tions can be identified. Second, PIK3CA mutations were
associated with BRCA proficient tumors. After validation
in larger series, triple negative tumors with PIK3CA mut-
ations can be candidates for agents targeting these onco-
genic pathways. To identify recurrent mutations associated
with chemotherapy or relapse, larger sample series are ur-
gently needed.
Additional files
Additional file 1: Figure S1. BRCA1 gene expression, measured by
RT-PCR, for BRCA1-methylated, mutated and non-mutated/non-methylated
triple negative breast cancer (TNBC) samples. This figure shows the association
between BRCA proficiency/deficiency and BRCA1 gene expression, as
measured by RT-PCR. Samples with either BRCA1 promoter methylation
or a BRCA1 mutation all had low gene expression values. (DOCX 134 kb)
Additional file 2: Table S1. 1977 Cancer Gene Panel. This file lists all
1,977 genes in the Cancer Gene Panel, used in this study. (XLS 111 kb)
Additional file 3: Table S2. Overview of sequencing statistics. (XLSX 48 kb)
Additional file 4: Table S3. List of all mutations. This file shows all
mutations passing thresholds as explained in “Methods”. The column
“confirmed” shows mutations that have been confirmed by either Sanger
Sequencing or deep whole exome sequencing in another research
project (unpublished data). The column “included in analysis” shows the
mutations that passed our threshold for putative driver mutations, based
on effect, SIFT, polyphen scores and COSMIC (see “Methods”). The column
“dubious” shows the mutations that might be dubious based on gene
length, expression or replication time [20]. (XLSX 64 kb)
Additional file 5: Table S4. Association between mutations and
chemotherapy response or relapse. This table shows the top five genes
associated with either response or relapse. No significant associations
were found. (DOCX 18 kb)
Additional file 6: Table S5. Association between relapse and pathway
mutations. This table shows the top five pathways associated with
relapse. No significant associations were found. (DOCX 14 kb)
Additional file 7: Table S6. Specific mutations within affected
pathways. This file shows all pathways with KEGG IDs, and mutations
affecting the different pathways. (XLSX 10 kb)
Additional file 8: Figure S2. Heatmap of all copy number aberrations
in the dataset. Samples are represented by rows, genomic regions by the
columns sorted on genomic order. Red identifies a high level gain or
amplification; blue a loss. (PNG 130 kb)
Additional file 9: Figure S3. Validation of TTK, TP53BP2 and genome-
wide copy number profiles with Nimblegen 135 K aCGH arrays. aCGH
and exome data, for the samples for which aCGH data were available
(three cases for TTK, five cases for TP53BP2). Arrow indicates respectively
the TTK and TP53BP2 locus. From page 3 on we show all 14 samples for
which we have both exome and aCGH data, irrespective of TTK and
TP53BP2 status. In these rainbow plots, the samples containing a TTK or
TP53BP2 gain are indicated with an arrow at the respective genomic
location. (PDF 1639 kb)
Additional file 10: Table S7. Comparison of top alterations listed by
Balko et al. (reference [30]) (A) and our study (B) for TCGA [3], Balko et al.
[31] and our study. Part A shows the top alterations as listed by Balko
(reference [30]) in our study and TCGA (reference [3]), part B shows the
top alterations in our study. (DOCX 17 kb)
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